Form 13-F position report

RANI THERAPEUTICS HLDGS INC

Reported by VANGUARD GROUP INC

Company profile Manager portfolio Source filing
RANI CUSIP 753018100 Manager CIK 0000102909
Latest reported change

Reported 799,679 shares, unchanged from the prior quarter.

Reported value -59.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 799,679 Quarter-end amount reported
Reported value $411,035 Fair value at quarter end
Consecutive quarters held 16 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q4 2025 Added 5,109,368 +4,224,759 (477.6%) < 0.01% $6,897,647 2026-01-29
Q3 2025 Added 884,609 +84,930 (10.6%) < 0.01% $442,305 2025-11-07
Q2 2025 Unchanged 799,679 0 (0.0%) < 0.01% $411,035 2025-08-11
Q1 2025 Added 799,679 +89,851 (12.7%) < 0.01% $1,007,596 2025-05-09
Q4 2024 Unchanged 709,828 0 (0.0%) < 0.01% $972,465 2025-02-11
Q3 2024 Unchanged 709,828 0 (0.0%) < 0.01% $1,533,228 2024-11-13
Q2 2024 Added 709,828 +24,525 (3.6%) < 0.01% $2,697,347 2024-08-13
Q1 2024 Added 685,303 +16,956 (2.5%) < 0.01% $2,131,292 2024-05-10
Q4 2023 Reduced 668,347 -742 (-0.1%) < 0.01% $2,218,912 2024-02-14
Q3 2023 Unchanged 669,089 0 (0.0%) < 0.01% $1,455,269 2023-11-14
Q2 2023 Unchanged 669,089 0 (0.0%) < 0.01% $2,756,646 2023-08-14
Q1 2023 Unchanged 669,089 0 (0.0%) < 0.01% $3,452,499 2023-05-15
Q4 2022 Added 669,089 +18,111 (2.8%) < 0.01% $3,947,625 2023-02-10
Q3 2022 Added 650,978 +317,849 (95.4%) < 0.01% $6,236,000 2022-11-14
Q2 2022 Added 333,129 +43,022 (14.8%) < 0.01% $3,441,000 2022-08-12
Q1 2022 Added 290,107 +4,561 (1.6%) < 0.01% $3,916,000 2022-05-13
Q4 2021 Added 285,546 +2,333 (0.8%) < 0.01% $4,668,000 2022-02-14
Q3 2021 New 283,213 +283,213 (0.0%) < 0.01% $5,047,000 2021-11-12
Institutional context

Who else reported the position

46 managers reported RANI THERAPEUTICS HLDGS INC for Q2 2025.

Manager Activity Shares Change % of reported 13F Reported value Tenure
ARMISTICE CAPITAL LLC New 3,151,354 +3,151,354 0.03% $1,619,481 1 qtr
VANGUARD GROUP INC This report Unchanged 799,679 0 < 0.01% $411,035 16 qtrs
Nan Fung Group Holdings Ltd Unchanged 493,584 0 0.4% $253,653 16 qtrs
UNITED SERVICES AUTOMOBILE ASSOCIATION Unchanged 302,743 0 0.02% $155,580 14 qtrs
TAKEDA PHARMACEUTICAL CO LTD Unchanged 203,190 0 0.53% $104,419 7 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 190,557 -5,660 < 0.01% $97,944 16 qtrs
KESTRA PRIVATE WEALTH SERVICES LLC Added 156,140 +16,984 < 0.01% $80,240 3 qtrs
CITADEL ADVISORS LLC New 137,349 +137,349 < 0.01% $70,584 6 qtrs
BlackRock Inc Added 118,652 +55,069 < 0.01% $60,975 4 qtrs
NORTHERN TRUST CORPORATION Reduced 102,911 -1,479 < 0.01% $52,886 16 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 11, 2025
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
0
Shared
0
None
799,679

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.